文献速递核素与放射性配体治疗

肝动脉内肽受体放射性核素治疗神经内分泌肿瘤肝转移:住院患者随机对照试验(LUTIA)

Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-28

27例1-2级胃肠胰神经内分泌肿瘤(GEP-NET)伴双叶肝转移患者随机接受经肝动脉左叶或右叶连续四周期[177Lu]Lu-DOTATATE动脉内PRRT,对侧叶经「二次通过」效应受照并作为对照叶。第一周期后24小时[177Lu]Lu-SPECT/CT示靶病灶T/N摄取比动脉叶17.4 vs 对照叶16.2(p=0.299),平均增加17%(1.17;95%CI [1.00; 1.37]),67%(18/27)患者T/N比值升高。结论:动脉内给药安全,但未带来临床显著的肿瘤摄取增加。

要点

  • 第一周期后动脉叶与对照叶T/N摄取比无显著差异:17.4 vs 16.2(p=0.299)。
  • T/N平均增加17%(1.17;95%CI [1.00; 1.37]),67%(18/27)患者出现任何程度升高。
  • 动脉内[177Lu]Lu-DOTATATE安全,但未显著提高肿瘤摄取。

核心结论

  • 动脉内[177Lu]Lu-DOTATATE安全,但未导致临床显著的肿瘤摄取增加。

研究设计与样本

  • 住院患者随机对照试验,27例1-2级GEP-NET伴双叶肝转移患者随机接受经肝动脉左叶或右叶连续四周期动脉内PRRT,对侧叶及肝外病灶经「二次通过」效应受照,对侧叶作为对照叶。
  • 基线增强CT每叶最多识别3个>3 cm转移灶为靶病灶,主要终点为第一周期后24小时[177Lu]Lu-SPECT/CT的肿瘤/非肿瘤(T/N)摄取比,两叶T/N比值采用配对样本t检验比较。

主要发现

  • 第一周期后T/N摄取比动脉叶17.4 vs 对照叶16.2(p=0.299),差异无统计学显著。
  • T/N平均增加17%(1.17;95%CI [1.00; 1.37])。
  • 67%(18/27)患者第一周期后T/N比值出现任何程度升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide receptor radionuclide therapy (PRRT) using [177Lu]Lu-DOTATATE has been shown to effectively prolong progression free survival in grade 1-2 gastroenteropancreatic neuroendocrine tumours (GEP-NET), but is less efficacious in patients with extensive liver metastases. The aim was to investigate whether tumour uptake in liver metastases can be enhanced by intra-arterial administration of [177Lu]Lu-DOTATATE into the hepatic artery, in order to improve tumour response without increasing toxicity. METHODS: Twenty-seven patients with grade 1-2 GEP-NET, and bi-lobar liver metastases were randomized to receive intra-arterial PRRT in the left or right liver lobe for four consecutive cycles. The contralateral liver lobe and extrahepatic disease were treated via a "second-pass" effect and the contralateral lobe was used as the control lobe. Up to three metastases (> 3 cm) per liver lobe were identified as target lesions at baseline on contrast-enhanced CT. The primary endpoint was the tumour-to-non-tumour (T/N) uptake ratio on the 24 h post-treatment [177Lu]Lu-SPECT/CT after the first cycle. This was calculated for each target lesion in both lobes using the mean uptake. T/N ratios in both lobes were compared using paired-samples t-test. FINDINGS: After the first cycle, a non-significant difference in T/N uptake ratio was observed: T/NIA = 17·4 vs. T/Ncontrol = 16·2 (p = 0·299). The mean increase in T/N was 17% (1·17; 95% CI [1·00; 1·37]). Of all patients, 67% (18/27) showed any increase in T/N ratio after the first cycle. CONCLUSION: Intra-arterial [177Lu]Lu-DOTATATE is safe, but does not lead to a clinically significant increase in tumour uptake.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ebbers SC, Barentsz MW, de Vries-Huizing DMV, et al. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging. 2023. PMID: 37897617. doi:10.1007/s00259-023-06467-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。